TECLens Company Research Report

Company Overview

• Name: TECLens, Inc.

• Mission: To deliver a unified platform technology offering lifelong therapeutic and refractive care, aiming to transform the landscape of vision care worldwide.

• Founded: 2013

• Founders: No information is available

• Key People:

• Thomas Dunlap - Chief Executive Officer, Board of Directors

• Patrick Lopath - Med-tech Entrepreneur, Innovator, and Operational Leader

• Deji Abraham - Founder at Wine Club Site

• Tom Welsh - Director of Engineering

• Headquarters: 9 Riverbend Dr. South, Stamford, CT 06907, United States

• Number of Employees: 2-10 employees

• Revenue: No information is available

• Known For: Developing non-invasive corneal cross-linking technology for refractive correction using the proprietary quantitative cross-linking (qCXL™) technology and the innovative CXLens® system.

Products

Quantitative Cross-Linking (qCXL™) Technology

• Description: A proprietary technology designed to gently reshape the cornea to address presbyopia and potentially other vision corrections. It is a comfortable, non-invasive, in-office procedure aimed at restoring near vision.

• Key Features:

• Utilizes UV-light delivered to the eye through a fiber optic-connected scleral contact lens.

• Provides real-time ultrasound feedback and patterned UV light delivery.

• Initially focused on presbyopia but exploring applications for hyperopia, progressive myopia in children, low-order myopia in adults, and keratoconus.

Recent Developments

• New Products/Features: No new products or features information is available.

• New Partnerships:

• Johnson & Johnson Innovation closed a Series A funding transaction as a co-lead investor in TECLens, focusing on non-incisional procedures for refractive correction.

• General Updates:

• TECLens actively hiring for various engineering positions in Stamford, Connecticut.

• Presented innovations at the EU Ophthalmology Futures Forum in October 2021.

• Recent publications include a study on Transepithelial Corneal Crosslinking and corneal biomechanics assessments in refractive surgery.

• Other Notable Achievements:

• Study led by Dr. Juan Batlle Jr. received First Place Poster at ASCRS 2020.

In conclusion, TECLens is committed to pioneering innovative non-invasive corneal reshaping technologies and expanding the applications of its qCXL™ technology to address global vision challenges, supported by significant investment partnerships.